Preclinical Evaluation

Critical Step Bridging Discovery and Clinical Development

Preclinical evaluation is a vital phase in the development of large molecule therapeutics, providing essential data on safety, efficacy, pharmacokinetics and toxicology before human clinical trials.

These studies establish biological plausibility, identify safe starting doses and support regulatory submissions, ensuring that investigational products are both effective and safe for patients.

Foundation for Efficient and Scalable Biologics Production

Cell line development (CLD) is a critical step in the development of biologics, shaping the efficiency, yield and quality of therapeutic proteins and antibodies.

Key Components of Preclinical Evaluation

Biological Activity & Pharmacodynamics

Assess the therapeutic mechanism of action and dose-response relationships using in vitro assays and relevant animal models. This confirms the investigational product’s intended biological effects.

Safety Pharmacology & Toxicology

Conduct acute, sub-chronic, and chronic toxicity studies to identify potential adverse effects, target organ toxicity and safe dose ranges. Safety pharmacology evaluates effects on vital systems such as cardiovascular, respiratory and central nervous systems.

Pharmacokinetics (ADME)

Study absorption, distribution, metabolism and excretion profiles to understand drug behavior in the body. These data guide dosing regimens and predict human pharmacokinetics.

Animal Models & Study Design

1 Species Selection

Choose appropriate animal species based on biological relevance, receptor homology and immunogenicity considerations. Commonly used species include rodents and non-rodents such as non-human primates.

2 Disease Models

Employ models that mimic human pathophysiology to evaluate efficacy and safety in relevant contexts.

3 Dose & Route of Administration

Determine dosing schedules and administration routes that reflect intended clinical use, ensuring translational relevance.

4 GLP Compliance

Adhere to Good Laboratory Practice standards to ensure data integrity and regulatory acceptance.

Special Considerations for Biologics

Immunogenicity Assessment

Evaluate the potential for immune responses against the biologic, which can impact safety and efficacy.

Species Specificity

Address challenges due to target specificity and cross-reactivity, often requiring the use of surrogate molecules or homologous proteins in animal studies.

Product-Related Impurities

Characterize and assess safety of impurities and variants unique to biologics to ensure comprehensive risk evaluation.

Regulatory Support & Reporting

Comprehensive Study Reports

Prepare detailed documentation summarizing study design, methods, results and interpretations to support IND and clinical trial applications.

Regulatory Communication

Facilitate interactions with agencies such as FDA and EMA, providing scientific rationale and addressing queries related to preclinical data.